Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought

Executive Summary

FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31

You may also be interested in...



FDA Gives “Fast Track” Wide Lane; Guidance Sets Few Limits On Criteria

FDA broadly defines the circumstances under which drugs and biologics can be approved under expedited approval mechanisms in a guidance published July 22

FDA Gives “Fast Track” Wide Lane; Guidance Sets Few Limits On Criteria

FDA broadly defines the circumstances under which drugs and biologics can be approved under expedited approval mechanisms in a guidance published July 22

FDA May Ask Congress For Funds To Boost Translational Research For Drugs

FDA is understood to be considering whether legislation could be useful to help promote translational research for pharmaceuticals

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel